Biotech companies seeking a financing partner need a strategic focus, says Cheryl Reicin in The Globe and Mail

March 05, 2008

A proliferation of life science M&A deals is turning the industry on its head and leaving no doubt that the area is not just vibrant but viable. But on this side of the pond, Canada—despite world-recognized research capabilities—is struggling to keep up. Canada's biggest hurdle to a sustained industry is financing.

Our neighbours to the south hold the key, says Cheryl Reicin. "There is such limited funding in Canada that the activity in Canada is mostly desperation sales." While big pharmaceutical companies are interested in their products, she adds, Canadian companies, desperate to stay afloat, are selling off their best assets—the research.

Tags:

Press Contact